BRISBANE, Calif., July 9, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Jonathan A. Leff, M.D., Executive Vice President, Research and Development of InterMune, will present at the JMP Securities 7th Annual Healthcare Conference in New York on Thursday, July 12 at 12:30 p.m. EDT.
To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.SOURCE InterMune, Inc.